OSD
Torkel Gren, Senior Director, Science & Technology Officer at Recipharm, discusses the advantages of an integrated approach to drug development that considers FIH trials from the beginning in Contract Pharma.
For full article see here:
Progressing a drug from early phase development to first in human (FIH) trials often presents a complex challenge in which there are many potential pitfalls. In fact, a poor safety profile leads to almost two thirds of projects being cancelled in their early stages. Supply of active pharmaceutical ingredients (APIs) is also often limited, presenting further difficulties and the need to develop simple formulations.
Drug companies are under pressure to quickly identify the most promising candidates and safely move them into clinical trials.